Vontobel Holding Ltd. Makes New $429,000 Investment in Revvity, Inc. (NYSE:RVTY)

Vontobel Holding Ltd. purchased a new position in Revvity, Inc. (NYSE:RVTY) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 3,922 shares of the company’s stock, valued at approximately $429,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. acquired a new position in shares of Revvity in the 3rd quarter valued at about $1,579,487,000. Ceredex Value Advisors LLC acquired a new position in shares of Revvity in the 4th quarter valued at about $108,353,000. Sumitomo Mitsui Trust Holdings Inc. acquired a new position in shares of Revvity in the 4th quarter valued at about $33,568,000. Boston Trust Walden Corp acquired a new position in shares of Revvity in the 4th quarter valued at about $25,154,000. Finally, KBC Group NV acquired a new position in shares of Revvity in the 3rd quarter valued at about $25,301,000. 86.65% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. Raymond James lifted their price objective on Revvity from $106.00 to $127.00 and gave the company an “outperform” rating in a research note on Friday, February 2nd. KeyCorp raised their target price on Revvity from $110.00 to $126.00 and gave the company an “overweight” rating in a report on Friday, February 2nd. Barclays raised their target price on Revvity from $92.00 to $105.00 and gave the company an “equal weight” rating in a report on Thursday, January 25th. UBS Group downgraded Revvity from a “buy” rating to a “neutral” rating and raised their target price for the company from $105.00 to $125.00 in a report on Tuesday, January 16th. Finally, Evercore ISI upgraded Revvity from an “in-line” rating to an “outperform” rating and raised their target price for the company from $88.00 to $125.00 in a report on Thursday, January 4th. Six investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $118.91.

Revvity Price Performance

RVTY stock opened at $103.49 on Wednesday. The company has a quick ratio of 1.77, a current ratio of 2.07 and a debt-to-equity ratio of 0.40. Revvity, Inc. has a 52-week low of $79.50 and a 52-week high of $135.67. The stock’s 50 day moving average is $104.74 and its two-hundred day moving average is $101.49. The company has a market capitalization of $12.78 billion, a PE ratio of 18.82, a P/E/G ratio of 2.63 and a beta of 1.09.

Revvity (NYSE:RVTY) last posted its quarterly earnings data on Thursday, February 1st. The company reported $1.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.15 by $0.10. Revvity had a return on equity of 7.41% and a net margin of 25.20%. The company had revenue of $695.90 million for the quarter. Analysts predict that Revvity, Inc. will post 4.65 earnings per share for the current fiscal year.

Revvity Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 10th. Shareholders of record on Friday, April 19th will be issued a dividend of $0.07 per share. The ex-dividend date of this dividend is Thursday, April 18th. This represents a $0.28 annualized dividend and a yield of 0.27%. Revvity’s dividend payout ratio is presently 5.09%.

Insiders Place Their Bets

In other news, insider Prahlad R. Singh sold 21,217 shares of Revvity stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $104.28, for a total value of $2,212,508.76. Following the completion of the transaction, the insider now owns 92,801 shares in the company, valued at approximately $9,677,288.28. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.60% of the stock is owned by company insiders.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.